{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:51:13Z","timestamp":1791327073517,"version":"4.3.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA222871"],"award-info":[{"award-number":["1R01CA222871"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P01 CA163222"],"award-info":[{"award-number":["5P01 CA163222"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01AR043369-22"],"award-info":[{"award-number":["5R01AR043369-22"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR072304"],"award-info":[{"award-number":["R01AR072304"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jid.2021.09.028","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T16:42:20Z","timestamp":1643992940000},"page":"1004-1006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-6605","authenticated-orcid":false,"given":"Abdullah Al","family":"Emran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-0575","authenticated-orcid":false,"given":"David E.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.09.028_bib1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.036","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses [published correction of Cell 2015;162:974\u201386]","volume":"169","author":"Chiappinelli","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jid.2021.09.028_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","article-title":"Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy","volume":"40","author":"Emran","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jid.2021.09.028_bib3","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3390\/cancers12082082","article-title":"Study of the female sex survival advantage in melanoma-A focus on X-linked epigenetic regulators and immune responses in two cohorts","volume":"12","author":"Emran","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2021.09.028_bib4","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2013598118","article-title":"Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma","volume":"118","author":"Falahat","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2021.09.028_bib5","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2021.09.028_bib6","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/\u03b2-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2021.09.028_bib7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib [published correction appears in J Clin Oncol 2019;37:355]","volume":"34","author":"Long","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2021.09.028_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jid.2021.09.028_bib9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2021.09.028_bib10","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.jid.2020.02.042","article-title":"EZH2 cooperates with DNA methylation to downregulate key tumor suppressors and IFN gene signatures in melanoma","volume":"140","author":"Tiffen","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.09.028_bib11","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jid.2021.08.437","article-title":"EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma","volume":"142","author":"Xu","year":"2022","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21023782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21023782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:26:03Z","timestamp":1758302763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21023782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0022202X21023782"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.09.028","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.08.437","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}